A multinational, observational retrospective study to evaluate the efficacy and safety of ponatinib in chronic myeloid leukemia (CML)
Latest Information Update: 29 Aug 2019
Price :
$35 *
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 29 Aug 2019 New trial record